We are live on
!
Find out more
Loomis, Sayles & Company Portfolio holdings
AUM
$74.3B
1-Year Est. Return
24.01%
This Fund
S&P 500
This Quarter
Est. Return
+9.81%
1 Year Est. Return
+24.01%
3 Year Est. Return
+109.67%
5 Year Est. Return
+145.58%
10 Year Est. Return
+623.12%
AUM
$79.2B
AUM Growth
+$3.07B
(+4%)
Cap. Flow
-$2.3B
Cap. Flow
% of AUM
-2.9%
Top 10 Holdings %
Top 10 Hldgs %
48.93%
Holding
809
New
117
Increased
205
Reduced
335
Closed
91
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$331M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
+$327M |
| 3 |
NVO
Novo Nordisk
NVO
|
+$319M |
| 4 |
Allison Transmission
ALSN
|
+$195M |
| 5 |
BA.PRA
Boeing Co 6.00% Series A Preferred Stock
BA.PRA
|
+$50M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$853M |
| 2 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
+$294M |
| 3 |
NVIDIA
NVDA
|
+$266M |
| 4 |
Netflix
NFLX
|
+$190M |
| 5 |
Meta Platforms (Facebook)
META
|
+$175M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.48% |
| 2 | Consumer Discretionary | 18.83% |
| 3 | Communication Services | 18.1% |
| 4 | Healthcare | 11.79% |
| 5 | Financials | 9.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
JPMorgan Chase
JPM
$950B
| $249M | 0.31% |
1,040,126
-42,841
| -4% | -$9.98M |
|
52
Cummins
CMI
$88.7B
| $247M | 0.31% |
707,164
+22,271
| +3% | +$7.82M |
|
53
TSMC
TSM
$2.18T
| $235M | 0.3% |
1,189,049
-42,924
| -3% | -$8.31M |
|
54
Danaher
DHR
$144B
| $234M | 0.3% |
1,020,865
+59,639
| +6% | +$14.7M |
|
55
Goldman Sachs
GS
$303B
| $211M | 0.27% |
368,259
-9,075
| -2% | -$5.06M |
|
|
BA.PRA
56
Boeing Co 6.00% Series A Preferred Stock
BA.PRA
$8.27B
| $157M | 0.2% |
+886,790
| New | +$50M |
|
57
Mercado Libre
MELI
$92.3B
| $151M | 0.19% |
89,076
-146
| -0.2% | -$284K |
|
58
Adobe
ADBE
$105B
| $139M | 0.17% |
311,491
+21,055
| +7% | +$10.4M |
|
59
Trane Technologies
TT
$106B
| $131M | 0.17% |
355,337
-9,443
| -3% | -$3.75M |
|
60
Doximity
DOCS
$4.88B
| $125M | 0.16% |
2,334,597
+62,366
| +3% | +$3.05M |
|
61
Alnylam Pharmaceuticals
ALNY
$29.3B
| $118M | 0.15% |
503,045
-22,258
| -4% | -$5.85M |
|
62
Accenture
ACN
$108B
| $118M | 0.15% |
334,192
-95,238
| -22% | -$34.3M |
|
63
HealthEquity
HQY
$8.75B
| $106M | 0.13% |
1,107,526
-19,119
| -2% | -$1.78M |
|
64
Arm
ARM
$302B
| $105M | 0.13% |
854,524
-42,176
| -5% | -$5.95M |
|
65
Builders FirstSource
BLDR
$8.04B
| $103M | 0.13% |
721,068
+59,092
| +9% | +$10.5M |
|
66
Merit Medical Systems
MMSI
$5.32B
| $103M | 0.13% |
1,065,265
-31,891
| -3% | -$3.18M |
|
67
Glaukos
GKOS
$10.6B
| $98.1M | 0.12% |
654,072
-19,679
| -3% | -$2.71M |
|
68
Procept Biorobotics
PRCT
$1.17B
| $97.2M | 0.12% |
1,207,060
-36,207
| -3% | -$3.09M |
|
69
Intapp
INTA
$2.91B
| $94.9M | 0.12% |
1,481,149
-11,471
| -0.8% | -$658K |
|
70
Casella Waste Systems
CWST
$5.69B
| $92.2M | 0.12% |
871,344
+22,368
| +3% | +$2.36M |
|
71
Hamilton Lane
HLNE
$5.57B
| $92.1M | 0.12% |
622,405
-162,896
| -21% | -$29M |
|
72
Workiva
WK
$3.54B
| $89.2M | 0.11% |
814,582
+86,207
| +12% | +$7.95M |
|
73
Arcosa
ACA
$7.11B
| $88.1M | 0.11% |
910,290
-9,709
| -1% | -$976K |
|
|
CWAN
74
DELISTED
Clearwater Analytics
CWAN
| $88M | 0.11% |
3,198,411
-96,071
| -3% | -$2.73M |
|
75
IQVIA
IQV
$39.3B
| $86.1M | 0.11% |
438,306
-258,394
| -37% | -$54.5M |
|
Similar funds
CBU
BC
Loomis, Sayles & Company's Q4 2024 Portfolio in Review
As of Q4 2024, Loomis, Sayles & Company held 809 positions worth $79.2B, up 4% from $76.2B the previous quarter. Its ten largest holdings account for 49% of the portfolio.
Loomis, Sayles & Company's Q4 2024 filing shows 117 new, 205 increased, 335 reduced and 91 closed positions. Its largest new stake was Boeing Co 6.00% Series A Preferred Stock: 886,790 shares worth $157M. The largest sale was Tesla, an estimated $853M.
By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 28% a quarter earlier, followed by Consumer Discretionary and Communication Services.
- Loomis, Sayles & Company's largest Q4 2024 buy was Boeing Co 6.00% Series A Preferred Stock: 886,790 shares worth $157M.
- Loomis, Sayles & Company added most to Regeneron Pharmaceuticals in Q4 2024, an estimated $331M increase.
- Loomis, Sayles & Company's biggest Q4 2024 reduction was Tesla, cutting an estimated $853M.
- Loomis, Sayles & Company fully exited Medpace in Q4 2024, selling an estimated $68.7M.
- Loomis, Sayles & Company's ten largest holdings make up 49% of its $79.2B portfolio in Q4 2024.
- Loomis, Sayles & Company opened 117 new positions and closed 91 in Q4 2024.
- Loomis, Sayles & Company's portfolio value rose 4% quarter-over-quarter to $79.2B.
Based on Loomis, Sayles & Company's 13F filing for Q4 2024, filed 12 Feb 2025.